Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Inclusion Criteria

• •1. Men or women ≥ 18 and ≤ 75 years of age at time of screening
• •2. Stable moderate to severe plaque psoriasis for at least 6 months before baseline
• •3. Moderate to severe psoriasis defined at screening and baseline by:
• •Body surface area (BSA) affected by plaque psoriasis of 10% or greater, and PASI score of 12 or greater, and static physician's global assessment score of 3 or greater
• •4. No known history of active tuberculosis
• •5. Subject is a candidate for systemic therapy or phototherapy procedures
• •6. Previous failure, inadequate response, intolerance, or contraindication to at least 1 conventional anti-psoriatic systemic therapy